---
uid: 20260215135500
title: Crohn's Disease & Vitamin D Deficiency
authors: Dr. Dimitris Tsoukalas (Clinic Post)
year: ~2023
url: https://www.drtsoukalas.com/nosos_tou_crohn___elleipsi_bitaminis_d-su-523.html
tags: [lit, clinic-tsoukalas, gut, IBD, crohns, vitD, inflammation, metabolomics]
aliases: [Tsoukalas-Crohns-VitD, Crohns-VitD-Def]
status: lit-full
parent-moc: [[55-MOCs/Nutrition/Gut]] | [[55-MOCs/Tsoukalas-Metabolomics]] | [[55-MOCs/Autoimmune]]
confidence: high
cited_refs: [Ref1_Ng_IBD, Ref2_Molodecky_IBD, Ref3_Fletcher_IBD, Ref4_Mouli_IBD, Ref5_Hlavaty_IBD, Ref6_LopezMunoz_IBD, Ref7_Vojinovic_VDR, Ref8_Golpour_VDR, Ref9_vonEssen_TCell, Ref10_Yang_Autoimmunity, Ref11_Murdaca_Autoimmune, Ref12_Ooi_VDRGut, Ref13_Chatterjee_VDRMicrobiome, Ref14_Krishnan_AntiCancer, Ref15_Vojinovic_AntiInflam, Ref16_Finamor_HighDose, Ref17_Sarandi_MetabProf, Ref18_TsoukalasCOVID, Ref19_Holler_Micronutrient, Ref20_Sussulini_Metabolomics]
---

# Crohn's Disease & Vitamin D Deficiency (Tsoukalas, ~2023)

**Source**: Dr Tsoukalas Clinic (Greek → EN translation/edits). **Edits**: Promo/booking stripped; reps consolidated; structured; wikilinks.

## TL;DR (Actionable)
- **80% Crohn's pts VitD def** → ↑ flares/inflam/gut barrier loss/bone/muscle.
- **Mechanisms**: VitD ↓ TNF/IL-6 via VDR; microbiome protection.
- **Supp**: Dose → monitor Metabolomics® (organic/fatty acids pred IBD).
- **Chain**: Links Hashimoto VitD [[20260215_Tsoukalas_Hashimoto_VitD_Full]].

## Key Mechanisms & Evidence
### VitD & Crohn's/IBD
VitD def in **80% Crohn's pts** → exacerbates flares/inflam/gut barrier/bone/muscle [[Ref1_Ng_IBD],[Ref2_Molodecky_IBD]].

**Immune Modulation**:
- ↓ Pro-inflam (TNF/IL-6) via VDR; ↑ anti-microbial peptides [[Ref7_Vojinovic_VDR],[Ref8_Golpour_VDR]].
- T-cell signaling control [[Ref9_vonEssen_TCell]].

**Gut/Microbiome**:
- VDR promotes healthy metabolites/microbiome; ↓ colitis [[Ref12_Ooi_VDRGut],[Ref13_Chatterjee_VDRMicrobiome]].

### Clinical Outcomes
- Global IBD rise; VitD def ↑ markers/activity; therapy ↓ flares [[Ref4_Mouli_IBD],[Ref5_Hlavaty_IBD],[Ref6_LopezMunoz_IBD]].

## Protocols & Recommendations
**High-Dose VitD**:
- **Dose**: Personalized 5,000 IU/day → target 50 ng/mL (monitor 3-5mo).
- **Monitor**: Metabolomic Analysis® (organic/fatty acids).
- **Safety**: Calcemia/oxalate watch; gut microbiome tie-in.

**Natural Sources** (Table):
| Food/Source | VitD Boost |
|-------------|------------|
| Fatty fish | High |
| Eggs/sun | Moderate |
| Mushrooms | Fill gaps |

## Metabolomic Analysis® for Crohn's
Tsoukalas protocol: Predicts IBD via:
- **Organic Acids**: VitD/C/mg/ω-3 status.
- **Fatty Acids**: ω-3/ω-6 ratio → inflam pred [[Ref17_Sarandi_MetabProf]].
- **Why Usable**: [[33-PhD/Biomarkers]] | [[Tsoukalas-Metabolomics.canvas]].

**Why Usable**: [[66-Nutrition/Gut]] | [[44-Clinic/RON/LEDGER]] (VitD inputs → flares/CRP ↓).

## Key Quotes
> "Vitamin D deficiency exacerbates the disease in Crohn's patients." (Intro)
> "VDR emerges as key player in gut flora." (Rochester study)
> "Metabolomics predicts IBD via organic/fatty acids." (Tsoukalas)

## Full Bibliography (Zotero-Ready)
| # | Title | Authors | Journal/Year | DOI/PMID/PMC/URL | Note Link |
|---|-------|---------|--------------|------------------|-----------|
|1| Worldwide Incidence IBD | Siew C Ng et al. | Lancet 2018 | PMID:29050646 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref1_Ng_IBDIncidence_20260215]] |
|2| Increasing Incidence IBD | Natalie A Molodecky | Gastroenterology 2012 | PMID:22001864 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref2_Molodecky_IBDInc_20260215]] |
|3| Role of VitD in IBD | Jane Fletcher et al. | Nutrients 2019 | PMC6566188 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref3_Fletcher_VitDIBD_20260215]] |
|4| VitD Therapy IBD | V P Mouli, A N Ananthakrishnan | Aliment Pharmacol Ther 2014 | PMID:24236989 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref4_Mouli_VitDIBD_20260215]] |
|5| VitD Therapy IBD Form/Dose | Tibor Hlavaty et al. | J Crohns Colitis 2015 | PMID:26046136 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref5_Hlavaty_VitDIBD_20260215]] |
|6| VitD Def Inflammatory Markers IBD | Pedro López-Muñoz et al. | Nutrients 2019 | PMID:31083541 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref6_LopezMunoz_IBD_20260215]] |
|7| VitD Receptor Agonists Anti-Inflam | Jelena Vojinovic | Ann N Y Acad Sci 2014 | PMID:24754474 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref7_Vojinovic_VDR_20260215]] |
|8| Antimicrobial Effects VitD | Ainoosh Golpour et al. | Eur J Microbiol Immunol 2019 | PMC6798578 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref8_Golpour_VDR_20260215]] |
|9| VitD T Cell Signaling | von Essen et al. | Nat Immunol 2010 | DOI:10.1038/ni.1851 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref9_vonEssen_TCell_20260215]] |
|10| VitD Autoimmunity Review | Chen-Yen Yang et al. | Clin Rev Allergy Immunol 2018 | PMC6047889 | [[22-Literature/Refs/Tsoukalas/Ref10_Yang_Autoimmunity_20260215]] |
|11| Emerging VitD Autoimmune | Giuseppe Murdaca | Autoimmun Rev 2019 | PMID:31323357 | [[22-Literature/Refs/Tsoukalas/Ref11_Murdaca_Autoimmune_20260215]] |
|12| VitD Gut Microbiome Colitis | Jot Hui Ooi et al. | J Nutr 2013 | PMID:23966330 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref12_Ooi_VDRGut_20260215]] |
|13| VitD Receptor Microbiome | Ishita Chatterjee et al. | Sci Rep 2020 | PMID:32355205 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref13_Chatterjee_VDRMicro_20260215]] |
|14| Anti-Cancer Anti-Inflam VitD | Aruna V Krishnan, David Feldman | Annu Rev Pharmacol Toxicol 2011 | PMID:20936945 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref14_Krishnan_VitD_20260215]] |
|15| VitD Receptor Anti-Inflam | Jelena Vojinovic | Ann N Y Acad Sci 2014 | PMID:24754474 | [[22-Literature/Refs/Tsoukalas/Crohns/Ref15_Vojinovic_AntiInflam_20260215]] |
|16| High Dose VitD Pilot | Danilo C Finamor et al. | Dermatoendocrinol 2013 | PMC3897595 | [[22-Literature/Refs/Tsoukalas/Ref16_Finamor_HighDose_20260215]] |
|17| Metab Profiling Chronic | Evangelia Sarandi et al. | Advances in Clinical Chemistry 2020 | DOI:10.1016/bs.acc.2020.06.003 | [[22-Literature/Refs/Tsoukalas/Ref17_Sarandi_MetabProf_20260215]] |
|18| COVID Micronutrients Metabolomics | Dimitris Tsoukalas, Evangelia Sarandi | BMJ Nutr Prev Heal 2020 | bmjnph-2020-000169 | [[22-Literature/Refs/Tsoukalas/Ref18_TsoukalasCOVID_20260215]] |
|19| Micronutrient Status Humans | Höller U et al. | TrAC Trends Anal Chem 2018 | - | [[22-Literature/Refs/Tsoukalas/Crohns/Ref19_Holler_Micronutrient_20260215]] |
|20| Metabolomics Fundamentals | A. Sussulini | Springer 2017 | - | [[22-Literature/Refs/Tsoukalas/Crohns/Ref20_Sussulini_Metab_20260215]] |

## All Created Notes (Link Hub)
- **Lit Core**: [[22-Literature/20260215_Tsoukalas_Crohns_VitD_Full]]
- **Refs (20)**: [[Ref1_Ng_IBDIncidence_20260215]] | ... | [[Ref20_Sussulini_Metab_20260215]]

## Atomic Notes Extracted (Strong Claims)
| Note | Path | Key Claim |
|------|------|-----------|
| [[66-Nutrition/Gut/20260215_VitD_Def_Crohns_Prevalence]] | Gut | 80% Crohn's VitD def → flares. |
| [[66-Nutrition/Autoimmune/20260215_VDR_Immune_IBD]] | Autoimmune | VDR ↓ TNF/IL-6. |
| [[66-Nutrition/Gut/20260215_VitD_Gut_Microbiome_Crohns]] | Gut | VDR microbiome protection. |
| [[66-Nutrition/Vitamins/20260215_VitD_Bone_Muscle_IBD]] | Vitamins | Bone/muscle complications. |
| [[44-Clinic/RON/20260215_Protocol_VitD_Crohns]] | RON | High-dose protocol. |
| [[33-PhD/Biomarkers/20260215_Metabolomics_IBD_Prediction]] | PhD/Biomarkers | Acids predict risk.

**Next**: Extract atomics → [[00-Inbox]] | RON ledger.
